Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.42 |
| ▸ | DRD3 | P35462 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | DRD4 | P21917 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18975217 | 1.00 | DRD2 (0.42) | DRD2DRD3MEN1KMT2AL3MBTL1 | |
| SCHEMBL3970694 | 0.89 | DRD2 (0.47) | DRD2DRD3MEN1KMT2ASLC6A3 | |
| SCHEMBL8860654 | 0.89 | DRD2 (0.47) | DRD2DRD3MEN1KMT2ASLC6A3 | |
| SCHEMBL17996818 | 0.89 | DRD2 (0.47) | DRD2DRD3MEN1KMT2ASLC6A3 | |
| SCHEMBL13833151 | 0.89 | DRD2 (0.47) | DRD2DRD3MEN1KMT2ASLC6A3 | |
| SCHEMBL5860445 | 0.89 | — | — | |
| SCHEMBL636364 | 0.89 | DRD2 (0.47) | DRD2DRD3MEN1KMT2ASLC6A3 | |
| SCHEMBL5523024 | 0.84 | HSD17B10 (0.40) | MEN1KMT2AL3MBTL1ALDH1A1PIK3CD | |
| SCHEMBL24688086 | 0.82 | MEN1 (0.50) | DRD2DRD3MEN1KMT2ASLC6A3 | |
| SCHEMBL17996819 | 0.82 | MEN1 (0.50) | DRD2DRD3MEN1KMT2ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114062091-B | Method for detecting hydroxyalkyl piperazine in flue gas desulfurizing agent | 安徽大学 | 2023-09-01 | — | — | CN | claimed |
| CN-114062091-A | Method for detecting hydroxyalkyl piperazine in flue gas desulfurizing agent | 安徽大学 | 2022-02-18 | — | — | CN | claimed |
| CN-114062091-B | Method for detecting hydroxyalkyl piperazine in flue gas desulfurizing agent | 安徽大学 | 2023-09-01 | — | — | CN | disclosed |
| CN-114062091-B | Method for detecting hydroxyalkyl piperazine in flue gas desulfurizing agent | 安徽大学 | 2023-09-01 | — | — | CN | disclosed |
| US-20220259180-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | UNIVERSITY OF MARYLAND, BALTIMORE | 2022-08-18 | — | — | US | disclosed |
| WO-2022120207-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-06-09 | — | — | WO | disclosed |
| CN-114062091-A | Method for detecting hydroxyalkyl piperazine in flue gas desulfurizing agent | 安徽大学 | 2022-02-18 | — | — | CN | disclosed |
| CN-114062091-A | Method for detecting hydroxyalkyl piperazine in flue gas desulfurizing agent | 安徽大学 | 2022-02-18 | — | — | CN | disclosed |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC | 2020-02-20 | — | — | US | disclosed |
| US-20180186791-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-07-05 | — | — | US | disclosed |
| US-8841324-B2 | Heterocyclic compounds as autotaxin inhibitors | MERCK PATENT GMBH (DE) | 2014-09-23 | — | — | US | disclosed |
| US-8138305-B2 | Glucagon-like peptide-1 (glp-1) receptor agonist; diabetes, obesity, glucagonomas, secretory disorders of the airway, metabolic disorder, arthritis, osteoporosis, central nervous system disease, restenosis and neurodegenerative disease. | IPSEN PHARMA S.A.S. (FR) | 2012-03-20 | — | — | US | disclosed |
| US-7977455-B2 | Analogues of GLP-1 | IPSEN PHARMA, S.A.S. (FR) | 2011-07-12 | — | — | US | disclosed |
| US-7897566-B2 | Analogues of GLP-1 | IPSEN PHARMA S.A.S. (FR) | 2011-03-01 | — | — | US | disclosed |
| US-20090197802-A1 | Analogues of GLP-1 | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. (FR) | 2009-08-06 | — | — | US | disclosed |
| US-20090149378-A1 | GLP-1 ANALOGUES | BIOMEASURE, INCORPORATED (US) | 2009-06-11 | — | — | US | disclosed |
| US-4992150-A | Telomer with alpha-olefin;oil and fuel additive | NIPPON OIL CO, LTD. (JP) | 1991-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259180-A1 | BROAD SPECTRUM ANTIVIRAL COMPOUNDS TARGETING THE SKI COMPLEX | EIF2AK2, MAVS, IRF3 | DRD2 4352/4885DRD3 4343/4885MEN1 3425/4885 |
| US-20090197802-A1 | Analogues of GLP-1 | GLP1R, IAPP, GIPR | DRD2 3921/4885DRD3 3370/4885MEN1 170/4885 |
| US-20200055860-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | DRD2 2030/4885DRD3 1366/4885MEN1 1084/4885 |
| US-20180186791-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | DRD2 2385/4885DRD3 1529/4885MEN1 1015/4885 |
| US-20090149378-A1 | GLP-1 ANALOGUES | GLP1R, IAPP, GIPR | DRD2 3911/4885DRD3 3706/4885MEN1 158/4885 |
| US-11168090-B2 | Substituted pyrazolo[1,5-a]pyrazines as RET kinase inhibitors | RET, BRAF, ROR1 | DRD2 2050/4885DRD3 1383/4885MEN1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.